Skip to main content
Equibles
ALLO logo

ALLO · Allogene Therapeutics, Inc. · Earnings Call Transcripts & Audio

Track ALLO — free

Use ALLO with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ALLO.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$1.60 -0.02 (-1.23%) At close · Sep 30
Russell 2000 member Rebalance outlook locked
Market Cap
$563.15M
Shares
345.49M
Volume · Sep 30 8.13M Avg daily vol (3M) 6.23M

Allogene Therapeutics, Inc. Earnings Call Transcripts

Quarterly earnings calls for Allogene Therapeutics, Inc. (ALLO), with available speaker-labelled transcripts, captured audio replays, call highlights, 8-K earnings releases and periodic filings. Investor days and conferences appear here too.

Pull transcripts and briefs through the earnings call transcript API or MCP →

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
▼44.9% $27,000 −$84.24M '22 Q3 22-11-02 ▼100% $26,000 −$97.28M '22 Q4 23-02-28 ▼23.1% $30,000 −$99.97M '23 Q1 23-05-03 ▼65.6% $22,000 −$79.23M '23 Q2 23-08-02 ▼18.5% $22,000 −$62.29M '23 Q3 23-11-02 ▼19.2% $21,000 −$85.78M '23 Q4 24-03-14 ▼26.7% $22,000 −$65.00M '24 Q1 24-05-13 ▼100% $ −$66.36M '24 Q2 24-08-07 ▼100% $ −$66.29M '24 Q3 24-12-02 ▼100% $ −$59.94M '24 Q4 25-03-13 ▼100% $ −$59.73M '25 Q1 25-05-13 · $ −$50.94M '25 Q2 25-08-13 · $ −$41.40M '25 Q3 25-11-06 · $ −$38.81M '25 Q4 26-03-12 LATEST · $4.64M −$42.68M '26 Q2 26-08-12
Earnings call
FY26 · Q2
2026-08-12
Allogene Therapeutics, Inc. (ALLO) Q2 2026 Earnings Call Transcript
Confident tone Regulatory designations and FDA engagement ALLO-316 (Traverse / renal cell carcinoma) Clinical site expansion / community access
Revenue
$4.64M
Diluted EPS
$-0.13
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-06-03
Allogene Therapeutics, Inc. (ALLO) June 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q1
2026-05-13
Allogene Therapeutics, Inc. (ALLO) Q1 2026 Earnings Call Transcript
Confident tone Allo-329 autoimmune program Semicel (cema-cel) Alpha-3 MRD interim analysis MRD as treatment-decision paradigm / Natera Clarity assay
Diluted EPS
$-0.18
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-03-12
Allogene Therapeutics, Inc. (ALLO) Q4 2025 Earnings Call Transcript
Positive tone ALPHA-3 trial in LBCL ALLO-329 in autoimmune disease Data readouts and proof points
Revenue
$*
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-06
Allogene Therapeutics, Inc. (ALLO) Q3 2025 Earnings Call Transcript
Confident tone ALLO-329 in autoimmune disease (Resolution study) Allogeneic platform scalability vs autologous ALPHA3 trial of cema-cel in first-line LBCL consolidation
Revenue
$
Diluted EPS
$-0.19
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-13
Allogene Therapeutics, Inc. (ALLO) Q2 2025 Earnings Call Transcript
Positive tone ALPHA3 / cema-cel trial design change ALLO-329 in autoimmune disease / RESOLUTION study Allogeneic platform differentiation and durability
Revenue
$
Diluted EPS
$-0.23
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-13
Allogene Therapeutics, Inc. (ALLO) Q1 2025 Earnings Call Transcript
Positive tone ALPHA3 pivotal trial (cema-cel, 1L LBCL) ALLO-329 RESOLUTION trial in autoimmune disease ALLO-316 TRAVERSE trial in renal cell carcinoma
Revenue
$
▼ 100% YoY
Diluted EPS
$-0.28
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-03-13
Allogene Therapeutics, Inc. (ALLO) Q4 2024 Earnings Call Transcript
Confident tone ALLO-501A pivotal ALPHA3 trial in LBCL ALLO-329 autoimmune expansion Upcoming catalysts and trial milestones
Revenue
$*
▼ 100% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-12-02
Allogene Therapeutics, Inc. (ALLO) Q3 2024 Earnings Call Transcript
Confident tone ALLO-329 dual CAR for autoimmune disease ALLO-316 in advanced renal cell carcinoma ALPHA3 pivotal trial for cema-cel in first-line LBCL
Revenue
$
▼ 100% YoY
Diluted EPS
$-0.32
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-07
Allogene Therapeutics, Inc. (ALLO) Q2 2024 Earnings Call
Revenue
$
▼ 100% YoY
Diluted EPS
$-0.35
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-13
Allogene Therapeutics, Inc. (ALLO) Q1 2024 Earnings Call Transcript
Confident tone Cema-cel / ALPHA3 pivotal trial in 1L LBCL ALLO-329 autoimmune program with Dagger ALLO-316 / TRAVERSE in renal cell carcinoma
Revenue
$22,000
▼ 26.7% YoY
Diluted EPS
$-0.38
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-03-14
Allogene Therapeutics, Inc. (ALLO) Q4 2023 Earnings Call Transcript
Confident tone ALLO-329 autoimmune disease CLL / ALPHA2 cohort Corporate pivot and strategy
Revenue
$21,000*
▼ 19.2% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-02
Allogene Therapeutics, Inc. (ALLO) Q3 2023 Earnings Call Transcript
Revenue
$22,000
▼ 18.5% YoY
Diluted EPS
$-0.37
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-02
Allogene Therapeutics, Inc. (ALLO) Q2 2023 Earnings Call Transcript
Revenue
$22,000
▼ 65.6% YoY
Diluted EPS
$-0.54
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-03
Allogene Therapeutics, Inc. (ALLO) Q1 2023 Earnings Call Transcript
Revenue
$30,000
▼ 23.1% YoY
Diluted EPS
$-0.69
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-02-28
Allogene Therapeutics, Inc. (ALLO) Q4 2022 Earnings Call Transcript
Revenue
$26,000*
▼ 100% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-02
Allogene Therapeutics, Inc. (ALLO) Q3 2022 Earnings Call Transcript
Revenue
$27,000
▼ 44.9% YoY
Diluted EPS
$-0.59
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-09
Allogene Therapeutics, Inc. (ALLO) Q2 2022 Earnings Call Transcript
Revenue
$64,000
▲ 45.5% YoY
Diluted EPS
$-0.56
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-04
Allogene Therapeutics, Inc. (ALLO) Q1 2022 Earnings Call Transcript
Revenue
$39,000
▼ 99.9% YoY
Diluted EPS
$-0.56
Rev · 7q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-02-23
Allogene Therapeutics, Inc. (ALLO) Q4 2021 Earnings Call Transcript
Revenue
$75.65M*
Rev · 6q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-04
Allogene Therapeutics, Inc. (ALLO) Q3 2021 Earnings Call Transcript
Revenue
$49,000
Diluted EPS
$-0.57
Rev · 6q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-08-04
Allogene Therapeutics, Inc. (ALLO) Q2 2021 Earnings Call Transcript
Revenue
$44,000
Diluted EPS
$-0.53
Rev · 5q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-05-05
Allogene Therapeutics, Inc. (ALLO) Q1 2021 Earnings Call Transcript
Revenue
$38.34M
Diluted EPS
$-0.25
Rev · 4q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2021-02-25
Allogene Therapeutics, Inc. (ALLO) Q4 2020 Earnings Call Transcript
Revenue
$*
Rev · 3q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-11-04
Allogene Therapeutics, Inc. (ALLO) Q3 2020 Earnings Call Transcript
Revenue
$
Diluted EPS
$-0.52
Rev · 3q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q2
2020-08-05
Allogene Therapeutics, Inc. (ALLO) Q2 2020 Earnings Call Transcript
Revenue
$
Diluted EPS
$-0.53
Rev · 2q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q1
2020-05-06
Allogene Therapeutics, Inc. (ALLO) Q1 2020 Earnings Call Transcript
Revenue
$
Audio Transcript Slides 8-K10-Q
Earnings call
FY19 · Q4
2020-02-27
Allogene Therapeutics, Inc. (ALLO) Q4 2019 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-K
Showing 1–28 of 28 earnings calls
Key facts CIK 1737287 CUSIP 019770106 13F (30d) 4 filings 4 filers Visit website Investor relations